Evidence map›Paper›PMID 27812829›Full record

ArticleExperimental & applied acarology2016

Anaplasma phagocytophilum in questing Ixodes ricinus ticks in southwestern Finland.

Jani J Sormunen, Ritva Penttinen, Tero Klemola, Eero J Vesterinen, Jari Hänninen

Abstract read
PubMed Publisher
In one paragraph

Article in Experimental & applied acarology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Molecular Detection ofAnimals : an open access journal from MDPI · 2024
    Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jani J SormunenDepartment of Biology, University of Turku, 20014, Turku, Finland. jani.j.sormunen@utu.fi.ORCID http://orcid.org/0000-0002-6763-8477
Ritva PenttinenDepartment of Biology, University of Turku, 20014, Turku, Finland.
Tero KlemolaDepartment of Biology, University of Turku, 20014, Turku, Finland.
Eero J VesterinenDepartment of Biology, University of Turku, 20014, Turku, Finland.
Jari HänninenArchipelago Research Institute, University of Turku, 20014, Turku, Finland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anaplasma phagocytophilum is the causative agent of an emerging tick-borne disease, human granulocytic anaplasmosis. While the bacterium has been reported from questing ticks in neighboring Sweden, Norway and Russia, the few surveys regarding questing ticks in Finland have thus far been negative. In the current study, the prevalence of A. phagocytophilum in Ixodes ricinus populations was evaluated in several study localities around southwestern Finland during 2013-2014. Some of these populations were previously screened and found negative for A. phagocytophilum in 2000. A total of 3158 I. ricinus collected by blanket dragging were screened for Anaplasma spp. using qPCR. Anaplasma were detected in 9.2% of adult ticks (n = 87) and 3.1% of nymphs (n = 979). All larval samples were negative for infection. All Anaplasma-positive samples were identified as A. phagocytophilum by sequencing. This is, to the best of our knowledge, the first report of the pathogen from questing ticks in Finland. Furthermore, the pathogen was detected from several localities found negative during the previous screening 13 years earlier.

Indexed as

Anaplasma phagocytophilumAnaplasmosisAnimalsArachnid VectorsDNA, BacterialEhrlichiosisFemaleFinlandHumansIxodesLarvaNymphPolymerase Chain ReactionRNA, Ribosomal, 16SSequence Analysis, DNADNA, BacterialRNA, Ribosomal, 16SAnaplasma phagocytophilumDNAFinlandIxodes ricinusqPCRQuesting tick

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.